Dr. Dan Wu reports

BAUSCH HEALTH'S ORAPHARMA CELEBRATES 25 YEARS OF ARESTIN (MINOCYCLINE HCL) MICROSPHERES

Bausch Health Companies Inc. and its dental product business OraPharma have seen the 25th anniversary milestone of Arestin (minocycline HCl) microspheres, one milligram, a locally administered antibiotic used as an adjunct to scaling and root planing for the reduction of pocket depth in adult patients with periodontitis. Arestin is supported by over two decades of clinical experience and remains the only Food and Drug Administration-approved locally applied antibiotic for this use.

Dan Wu, PhD. senior director, pharmaceutical sciences and technology, Bausch Health, and a member of the development team behind Arestin, reflected: "The why behind developing Arestin began with recognizing that periodontal disease is a localized, chronic bacterial condition and that clinicians had no targeted way to help address it. There was a gap in treatment, and Arestin was developed to help fill that need by delivering antibiotic therapy directly into the periodontal pocket, using tiny microspheres that release the antibiotic gradually over time before naturally biodegrading."

Periodontal disease remains one of the most prevalent chronic oral health conditions globally, affecting more than one billion people. As part of comprehensive periodontal disease management, many dental professionals have incorporated Arestin with scaling and root planing.

"Reaching Arestin's 25-year milestone as the only FDA-approved locally applied antibiotic reflects our commitment to periodontal care," said Tom Stern, vice-president and general manager of the OraPharma business, Bausch Health's dentistry division. "As we recognize this legacy, we are equally focused on the future -- one defined by innovation and deeper collaboration with the dental community. Building on Arestin's impactful history, we continue to support non-surgical periodontal treatment for appropriate patients."

OraPharma continues to advance its commitment to periodontal health, including recent commercial expansion into Canada and Puerto Rico, aimed at improving access to treatment options in areas with unmet needs.

About Bausch Health Companies Inc.

Bausch Health is a global, diversified pharmaceutical company enriching lives through its relentless drive to deliver better health care outcomes. It develops, manufactures and markets a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through its controlling interest in Bausch + Lomb Corp. Its ambition is to be a globally integrated health care company, trusted and valued by patients, HCPs, employees and investors. OraPharma is a specialty pharmaceutical company committed to partnering with dental professionals to improve oral health.

We seek Safe Harbor.